Analyst ratings for Milam Pharmaceuticals milum Estimates for the past quarter range from bullish to bearish, according to four analysts.
The table below provides a concise summary of recent ratings by analysts, provides an insight into how sentiment has changed over the past 30 days, and shows how it compares to the previous month from a holistic perspective.
strong | Slightly bullish | indifference | Slightly bearish | bearish | |
---|---|---|---|---|---|
Total number of ratings | 2 | 2 | 0 | 0 | 0 |
the last 30d | 0 | 1 | 0 | 0 | 0 |
1 minute ago | 0 | 0 | 0 | 0 | 0 |
2 minutes ago | 0 | 1 | 0 | 0 | 0 |
3 minutes ago | 2 | 0 | 0 | 0 | 0 |
Analyst-rated 12-month price targets reveal further insight with an average target of $55.25, a high of $64.00 and a low of $35.00. This current average represents a -19.93% decrease from the previous average target price of $69.00.
Analyst Rating Analysis: Detailed Breakdown
A comprehensive study of how financial experts perceive Milam Pharmaceuticals from its recent analyst actions. Below is a detailed overview of the key analysts, their recent ratings, and adjustments to their ratings and price targets.
Analyst | analyst company | action taken | evaluation | Current target price | Previous target price |
---|---|---|---|---|---|
josh simmer | cantor fitzgerald | maintain | Overweight | $35.00 | – |
Jonathan Wolleven | JMP Securities | maintain | market outperformance | $64.00 | – |
steven seedhouse | raymond james | lower body | strong buy | $64.00 | $78.00 |
Ed Arce | HC Wainwright & Co. | lower body | buy | $58.00 | $60.00 |
Key insights:
- Action taken: Analysts frequently update their recommendations based on changes in market conditions and company performance. Whether they “maintain”, “increase” or “decrease” their stance reflects their reaction to recent developments related to Milam Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.
- evaluation: Analysts scrutinize ratings and assign qualitative values ranging from “outperform” to “underperform.” These ratings convey expectations about Milam Pharmaceuticals’ relative performance compared to the broader market.
- target price: Analysts study price target trends and provide estimates of the future value of Milam Pharmaceuticals stock. This research reveals that analyst expectations have changed over time.
Understanding these analyst ratings and associated financial metrics can provide valuable insight into Milam Pharmaceuticals’ market position. Use rating charts to stay informed and make strategic decisions.
Get the latest information on analyst ratings for Mirum Pharmaceuticals.
If you’re interested in tracking small-cap stock news and performance, you can start tracking it here.
Delving into the background of Milam Pharmaceuticals
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on identifying, acquiring, developing and commercializing new treatments for debilitating rare and rare diseases. The company’s product, LIVMARI, is a novel orally administered, minimally absorbed ileal bile acid transporter “IBAT” inhibitor (IBATi) for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). Approved as a medicine. He is involved in the development of malarixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS), as well as vorixibat for the treatment of adult patients with cholestatic liver disease.
Mirum Pharmaceuticals Financial Performance Breakdown
Market capitalization analysis: The company has a large presence, and its market capitalization exceeds the industry average. This reflects considerable size and strong market awareness.
Increased revenue: Mirum Pharmaceuticals’ three-month earnings growth is noteworthy. As of September 30, 2023, the company had approximately 154.13%. This represents a significant increase in the company’s top-line profits. Compared to its peers, its revenue growth has lagged behind its peers. The company achieved a lower growth rate than the average of its healthcare industry peers.
Net profit margin: Mirum Pharmaceuticals’ net profit margin exceeds industry standards, highlighting the company’s excellent financial performance.impressive -49.42% With high net profit margins, the company manages costs effectively and achieves high profitability.
Return on equity (ROE): Milam Pharmaceuticals’ ROE is below industry standards, indicating difficulty in efficiently utilizing equity capital. ROE is -13.57%, Companies may face challenges in providing satisfactory returns to shareholders.
Return on assets (ROA): Mirum Pharmaceuticals’ financial strength is reflected in its outstanding ROA, which is above the industry average.Achieve superior ROA -4.31%, The company has demonstrated efficient use of assets and strong financial health.
Debt management: Due to the high debt-to-equity ratio, 1.14Milam Pharmaceuticals faces challenges in effectively managing its debt levels, presenting a potential financial strain.
What is an analyst rating?
Within the realm of banking and financial systems, analysts specialize in reporting on specific stocks or defined sectors. Their job includes attending company conference calls and meetings, examining company financial statements, and communicating with insiders to issue “analyst ratings” on stocks. Analysts typically evaluate and rate each stock once per quarter.
Beyond standard ratings, some analysts contribute to forecasting metrics such as growth forecasts, revenue, and revenue, providing additional guidance to investors. Users of Analyst Ratings should keep in mind that this professional advice is formed by a human perspective and is subject to change.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.